AlphAIAlphAI — Financial news for AI agents
investing.com$NVMI

Nova earnings beat by $0.09, revenue topped estimates

Nova (NVMI) reported Q3 EPS of $2.86, beating estimates by $0.09, with revenue at $287.8M, topping expectations. The company guided Q4 2026 EPS to $3.03-$3.18 and revenue to $305.00M-$315.00M, slightly below consensus. NVMI stock is down 24.85% over 3 months and 5.95% over 12 months.

Original reporting
investing.com
Published Nov 5, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NVMI
Neutral
medium confidence
Mentioned
$NVMI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NVMINeutralMed
01

Why it matters

Earnings beat and guidance slightly above consensus may prompt short‑term buying interest, but the small magnitude limits broader impact.

02

Market read

Primary relevance to NVMI shareholders; limited spillover to sector.

03

What to watch

Cash burn and balance‑sheet health were not discussed but could affect valuation.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Nova (NVMI) is a micro‑cap biotech listed on NASDAQ. The article provides its Q3 earnings and Q4 guidance.

Company-level read

Ticker impact

$NVMINeutralMedium confidence
Context

Nova reported Q3 earnings beat EPS by $0.09 and revenue beat, plus provided Q4 guidance.

Expected impact

potential modest upside as market prices in the EPS beat and guidance above consensus

Evidence & confidence

The beat is small and guidance is close to consensus, limiting upside but still positive.

Market effects

Sector

Small‑cap biotech earnings may influence peer sentiment but limited sector impact.

Regional

Primarily U.S. market; no broader regional effect.

Global

Low global relevance beyond niche investors.

Counterpoint

What could challenge this read

The beat is marginal; investors may view guidance as insufficient and sell on expectations of slower growth.

Key entities

  • Company
    Nova

    NASDAQ‑listed biotech reporting Q3 results.

Read at source← All news

StoryNova posts record Q3 results and forecasts higher Q4 revenue

Also covered by

4 outlets

Related articles

$NVMIMed

Nova Q3 Earnings Call Highlights

Nova (NVMI) reported strong Q3 results, with record advanced packaging sales and significant demand for its WMC platform. Logic and foundry accounted for 61% of product revenue. The company forecasted Q4 revenue of $305M-$315M and expects GAAP EPS of $2.78-$2.94. Nova ended Q3 with $1.8B in cash and repurchased $38.5M of shares. It plans to discuss future strategy at an investor day in March 2027.

finance.yahoo.com
$NVMIMed

Nova Ltd (NVMI) Q3 2026 Earnings Call Highlights: Record Revenue, $1 Billion Milestone

Nova Ltd (NVMI) reported record Q3 2026 revenue, reaching $1 billion. The company faces supply chain constraints and expects new competition in materials metrology. Gross margin is guided to remain flat at 59%. Operating expenses are expected to increase in Q4 2026 due to higher R&D spending. CEO Gabriel Waisman highlighted growth opportunities in memory and gate-all-around metrology, with strong demand for the Metrion tool despite longer lead times.

finance.yahoo.com
$NVMIHighAI 8/10

Nova (NVMI) Q3 2026 Earnings Call Transcript

Nova (NVMI) reported Q3 2026 revenue of $287.8M, up 13% QoQ and 28% YoY, driven by strong demand in memory, advanced packaging, and logic segments. The company expects to exceed $1B in annual revenue, a year ahead of plan. Q4 guidance projects revenue between $305M-$315M and EPS between $2.78-$2.94 (GAAP) and $3.03-$3.18 (non-GAAP).

finance.yahoo.com